| Barry, Peter |
| Recruiting | N/A | 1200 | Europe, RoW | | Uppsala University, Uppsala University Hospital, Royal Marsden NHS Foundation Trust, Westmead Breast Cancer Institute, Sydney University, Sydney, Australia, Breast Unit, University Campus Biomedico, Rome, Italy | Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Invasive, Breast Asymmetry | 01/26 | 12/32 | | |
| Completed | N/A | 80 | Europe | Use of Acoustic and color imaging doppler during surgery for breast cancer | Royal Marsden NHS Foundation Trust | Breast Cancer | 01/24 | 01/24 | | |
| Recruiting | N/A | 224 | Europe | Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics | Endomagnetics Ltd. | Breast Cancer | 12/25 | 06/26 | | |
| HARRINGTON, Kevin |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix, Nanobiotix SA | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
| Completed | 2 | 149 | Europe | bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel | European Organisation for Research and Treatment of Cancer - EORTC | Salivary Gland Cancer | 08/23 | 02/24 | | |
| Active, not recruiting | 2 | 194 | Europe, US, RoW | ISA101b, Cemiplimab, Placebo | ISA Pharmaceuticals, Regeneron Pharmaceuticals | Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive | 09/24 | 06/25 | | |
| Active, not recruiting | 2 | 352 | Europe, Canada, US | tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin | Seagen Inc., Genmab, Merck Sharp & Dohme LLC | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 02/26 | 11/26 | | |
| Active, not recruiting | 2 | 65 | Europe, US, RoW | ISA101b, Cemiplimab | ISA Pharmaceuticals, Regeneron Pharmaceuticals | Squamous Cell Carcinoma of the Oropharynx | 06/24 | 12/24 | | |
|
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC |
|
|
| Active, not recruiting | 2 | 95 | Europe, US | Pembrolizumab (KEYTRUDA®) and PDS0101 | PDS Biotechnology Corp., Merck Sharp & Dohme LLC | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 06/25 | 06/25 | | |
|
| Recruiting | 2 | 340 | Europe, US | RP1, nivolumab, Opdivo | Replimune Inc., Bristol-Myers Squibb | Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC | 12/25 | 12/28 | | |
|
|
|
NCT05608876: A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer |
|
|
| Recruiting | 2 | 37 | Europe, RoW | Tigilanol Tiglate, EBC-46 | QBiotics Group Limited | Head and Neck Cancer | 08/25 | 10/26 | | |
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
|
|
| Withdrawn | 2 | 130 | Europe, US, RoW | RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab | Replimune Inc., Bristol-Myers Squibb | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 03/26 | 06/26 | | |
INSIGHT-2, NCT04242459: Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers |
|
|
| Recruiting | 1/2 | 73 | Europe | Adaptive Radiotherapy | Royal Marsden NHS Foundation Trust | Head and Neck Cancer | 05/24 | 05/24 | | |
| Not yet recruiting | 1/2 | 18 | Europe | Ixovex-1, Pembrolizumab, Keytruda | Psivac Ltd, IQVIA Biotech | Solid Tumor, Head and Neck Cancer | 01/27 | 01/27 | | |
| Recruiting | 1/2 | 100 | Europe | Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT) | T3 Pharmaceuticals AG | Advanced Solid Tumor | 02/26 | 10/26 | | |
Patriot, NCT02223923: Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours |
|
|
| Active, not recruiting | 1 | 87 | Europe | AZD6738, Palliative radiotherapy | Royal Marsden NHS Foundation Trust, AstraZeneca, Cancer Research UK, RM/ICR Biomedical Research Centre | Solid Tumour Refractory to Conventional Treatment | 12/23 | 12/23 | | |
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours |
|
|
| Active, not recruiting | 1 | 123 | Europe, US | RP3, Nivolumab | Replimune Inc., Bristol-Myers Squibb | Advanced Solid Tumor | 11/26 | 11/26 | | |
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck |
|
|
| Active, not recruiting | 1 | 36 | Europe | NG-641, Pembrolizumab | Akamis Bio | Squamous Cell Carcinoma of the Head and Neck | 09/24 | 10/24 | | |
| Recruiting | 1 | 36 | Europe | RP2, nivolumab, Opdivo | Replimune Inc. | Cancer | 10/26 | 04/28 | | |
|
|
| Harrington |
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC |
|
|
| Active, not recruiting | 2 | 95 | Europe, US | Pembrolizumab (KEYTRUDA®) and PDS0101 | PDS Biotechnology Corp., Merck Sharp & Dohme LLC | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 06/25 | 06/25 | | |
|
